PubRank

Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease

Clinical Trial ID NCT01720719

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01720719

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Nonalcoholic fatty liver disease. N Engl J Med 2002 22.41
2 The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005 15.74
3 Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010 13.33
4 Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2004 8.36
5 Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002 6.79
6 Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007 4.42
7 Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010 4.37
8 Abdominal fat: standardized technique for measurement at CT. Radiology 1999 4.25
9 Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003 4.05
10 Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2007 3.83
11 Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006 2.88
12 Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000 2.88
13 Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol 2005 2.67
14 Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2010 2.63
15 Visceral adiposity and incident coronary heart disease in Japanese-American men. The 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study. Diabetes Care 1999 2.25
16 Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000 2.17
17 Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004 2.08
18 An assessment of statin safety by hepatologists. Am J Cardiol 2006 1.78
19 Minimum waist and visceral fat values for identifying Japanese Americans at risk for the metabolic syndrome. Diabetes Care 2007 1.78
20 Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004 1.78
21 A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006 1.74
22 Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001 1.73
23 New insights into the diversity and function of neuronal immunoglobulin superfamily molecules. Annu Rev Neurosci 2003 1.58
24 Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging 2008 1.56
25 Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997 1.49
26 Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy. Am J Gastroenterol 2003 1.48
27 Hepatic lipid accumulation in healthy subjects: a comparative study using spectral fat-selective MRI and volume-localized 1H-MR spectroscopy. Magn Reson Med 2006 1.28
28 Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 2004 1.23
29 Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008 1.18
30 Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004 1.05
31 Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003 0.99
32 Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 2008 0.96
33 Identification of waist circumference cutoffs for abdominal obesity in the Chinese population: a 7.8-year follow-up study in the Shanghai urban area. Int J Obes (Lond) 2009 0.92
34 Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2005 0.89
35 Liver biochemistry abnormalities in a quaternary care lipid clinic database. Ann Hepatol 2008 0.82
36 Proton magnetic resonance spectroscopy and ultrasound for hepatic fat quantification. Hepatol Res 2010 0.80
37 [Measurement of intrahepatic triglyceride stores by 1H magnetic resonance spectroscopy: study with rat models and in patients]. Zhonghua Yi Xue Za Zhi 2008 0.77
Next 100